{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:22:24Z","timestamp":1790907744897,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"922","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravesical bacille Calmette-Gu\u00e9rin (BCG) has been used by urologists for several years after its first reported use as a cancer therapy in the 1930s. Morales in 1976 described the usage of BCG as a once weekly intravesical instillation for six weeks; this is a treatment regimen that still exists today. Its success as a treatment depends on it being used appropriately. It is employed: (1) to treat carcinoma in situ or occasionally residual papillary tumours; (2) to reduce the number and frequency of recurrent high grade superficial tumours; and (3) to prevent disease progression (although this remains a controversial point, on which there is no consensus view). Unfortunately, the more widespread use of BCG is often limited due its high side effect profile. Present research is directed towards reducing its side effect profile, improving its efficacy, and understanding its exact mechanism of action, which is not fully understood.<\/jats:p>","DOI":"10.1136\/pmj.78.922.449","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T19:54:10Z","timestamp":1033502050000},"page":"449-454","source":"Crossref","is-referenced-by-count":45,"title":["Use of bacille Calmette-Gu\u00e9rin in superficial bladder cancer"],"prefix":"10.1093","volume":"78","author":[{"given":"J-P","family":"Meyer","sequence":"first","affiliation":[{"name":"Bristol Urological Institute, Southmead Hospital , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Persad","sequence":"additional","affiliation":[{"name":"Bristol Royal Infirmary , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Gillatt","sequence":"additional","affiliation":[{"name":"Bristol Urological Institute, Southmead Hospital , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,8,1]]},"reference":[{"key":"2023042416533525000_R1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0022-5347(17)53725-8","article-title":"Prognostic parameters in superficial bladder cancer: an analysis of 315 cases","volume":"127","author":"Lutzeyer","year":"1982","journal-title":"J Urol"},{"key":"2023042416533525000_R2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1464-410x.2001.00948.x","article-title":"The management of superficial bladder cancer","volume":"87","author":"Oosterlinck","year":"2001","journal-title":"BJU Int"},{"key":"2023042416533525000_R3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors or primary superficial bladder cancer","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"2023042416533525000_R4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1464-410X.1998.00848.x","article-title":"Long-term survival of patients with bladder tumours: the significance of risk factors","volume":"82","author":"Zieger","year":"1998","journal-title":"Br J Urol"},{"key":"2023042416533525000_R5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1464-410x.2000.00547.x","article-title":"Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression","volume":"85","author":"Zieger","year":"2000","journal-title":"BJU Int"},{"key":"2023042416533525000_R6","first-page":"48","article-title":"Early history of BCG","volume-title":"BCG vaccination against tuberculosis","author":"Guerin","year":"1957"},{"key":"2023042416533525000_R7","first-page":"97","volume":"9","author":"Pearl","year":"1929","journal-title":"Cancer and tuberculosis"},{"key":"2023042416533525000_R8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(69)92648-8","article-title":"Active immunotherapy for acute lymphoblastic leukaemia","volume":"i","author":"Mathe","year":"1969","journal-title":"Lancet"},{"key":"2023042416533525000_R9","first-page":"127","article-title":"Extracutaneous delayed hypersensitivity, particularly in guinea pig bladder","volume":"10","author":"Coe","year":"1966","journal-title":"Immunology"},{"key":"2023042416533525000_R10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavity BCG in the treatment of superficial bladder tumours","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"2023042416533525000_R11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"BCG immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"2023042416533525000_R12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0022-5347(17)40067-X","article-title":"The response of patients with superficial bladder cancer to a second course of intravesical BCG","volume":"143","author":"Bretton","year":"1990","journal-title":"J Urol"},{"key":"2023042416533525000_R13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical BCG for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"2023042416533525000_R14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance BCG immunotherapy for recurrent TA, T1 and CIS TCC of the bladder: a randomised Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"2023042416533525000_R15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","article-title":"BCG treatment of existing papillary cancer and carcinoma in situ of the bladder","volume":"75","author":"Akaza","year":"1995","journal-title":"Cancer"},{"key":"2023042416533525000_R16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1464-410X.1992.tb15730.x","article-title":"Outcome in carcinoma in situ of bladder treated with intravesical BCG","volume":"70","author":"Harland","year":"1992","journal-title":"Br J Urol"},{"key":"2023042416533525000_R17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1464-410X.1995.tb07307.x","article-title":"Analysis of early failures after intravesical installation therapy with BCG for carcinoma in situ of the bladder","volume":"75","author":"Merz","year":"1995","journal-title":"Br J Urol"},{"key":"2023042416533525000_R18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","article-title":"Long term results of intravesical therapy for superficial bladder cancer","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"2023042416533525000_R19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomised prospective study comparing long term intravesical installations of MMC and BCG in patients with superficial bladder cancer","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"2023042416533525000_R20","first-page":"282A","article-title":"SWOG 8795. A randomised comparison of BCG and MMC prophylaxis in stage Ta & T1 transitional cell carcinoma of the bladder","volume":"149","author":"Lamm","year":"1993","journal-title":"J Urol"},{"key":"2023042416533525000_R21","first-page":"27","article-title":"Prospective randomised study of adjuvant therapy after complete resection of superficial bladder cancer: MMC vs BCG vs TUR alone","volume-title":"Immunotherapy of urological tumours","author":"Rubben","year":"1990"},{"key":"2023042416533525000_R22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomised study of intravesical mitomycin C, BCG-tice and BCG-rivm treatment in pTa, pT1 papillary carcinoma and CIS of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol"},{"key":"2023042416533525000_R23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"BCG therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"2023042416533525000_R24","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomised trial of intravesical doxorubicin and immunotherapy with BCG of transitional cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"2023042416533525000_R25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose of BCG regimen in superficial bladder cancer. Is it effective?","volume":"146","author":"Pagano","year":"1991","journal-title":"J Urol"},{"key":"2023042416533525000_R26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"BCG versus doxorubicin versus thiotepa: a randomised prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"key":"2023042416533525000_R27","first-page":"494A","article-title":"Final report on a randomised multicentre trial on adjuvant therapy in superficial bladder cancer. TUR only vs TUR & MMC vs TUR & BCG","volume":"155","author":"Krege","year":"1996","journal-title":"J Urol"},{"issue":"1","key":"2023042416533525000_R28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical installations: recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur Urol"},{"key":"2023042416533525000_R29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0022-5347(05)68078-0","article-title":"Interference of modern antibacterials with bacillus Calmette-Gu\u00e9rin viability","volume":"163","author":"Durek","year":"1999","journal-title":"J Urol"},{"key":"2023042416533525000_R30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"2023042416533525000_R31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","article-title":"Requirement of a thymus dependent immune response for BCG mediated antitumour activity","volume":"137","author":"Ratliff","year":"1987","journal-title":"J Urol"},{"key":"2023042416533525000_R32","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-5347(17)42445-1","article-title":"Role of fibronectin in intravesical BCG therapy for superficial bladder cancer","volume":"139","author":"Ratliff","year":"1988","journal-title":"J Urol"},{"key":"2023042416533525000_R33","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","article-title":"Internalisation of BCG by bladder tumour cells","volume":"145","author":"Beich","year":"1991","journal-title":"J Urol"},{"key":"2023042416533525000_R34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"key":"2023042416533525000_R35","first-page":"208","article-title":"Understanding the most successful immunotherapy for cancer","volume":"2","author":"Jackson","year":"1994","journal-title":"The Immunologist"},{"key":"2023042416533525000_R36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1464-410X.1989.tb05187.x","article-title":"HLA-DR expression by high grade superficial bladder cancer treated with BCG","volume":"63","author":"Prescott","year":"1989","journal-title":"Br J Urol"},{"key":"2023042416533525000_R37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","article-title":"BCG immunotherapy induces ICAM-1 expression on bladder tumours","volume":"47","author":"Jackson","year":"1994","journal-title":"J Clin Pathol"},{"key":"2023042416533525000_R38","first-page":"4286","article-title":"Murine bladder carcinoma cells present antigen to BCG specific CD4 T cells","volume":"52","author":"Lattime","year":"1992","journal-title":"Cancer Res"},{"key":"2023042416533525000_R39","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0022-5347(17)35941-4","article-title":"Dissecting the immunobiological effects of bacillus Calmette-Gu\u00e9rin organisms in vitro: evidence of a distinct BCG activated killer (BAK) cell phenomenon","volume":"150","author":"Bohle","year":"1993","journal-title":"J Urol"},{"key":"2023042416533525000_R40","first-page":"697","article-title":"Bacillus Calmette-Gu\u00e9rin organisms directly affect the growth of bladder tumour cells","volume":"5","author":"Jackson","year":"1994","journal-title":"Int J Urol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/78\/922\/449\/50040930\/postgradmedj-78-449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/78\/922\/449\/50040930\/postgradmedj-78-449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:54:04Z","timestamp":1682355244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/78\/922\/449\/7045878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":40,"journal-issue":{"issue":"922","published-online":{"date-parts":[[2002,8,1]]},"published-print":{"date-parts":[[2002,8,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.78.922.449","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,8]]},"published":{"date-parts":[[2002,8,1]]}}}